Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,324,192 | 968,279 | 524,068 | 433,433 | 1,330,813 |
| Depreciation Amortization | 32,489 | 23,751 | 14,630 | 5,281 | 19,562 |
| Accounts receivable | -2,360 | -1,945 | -787 | 3,171 | -4,551 |
| Other Working Capital | 1,076,447 | 704,241 | 451,571 | 225,771 | 887,371 |
| Other Operating Activity | 59,055 | -31,651 | -29,422 | -71,580 | 535,791 |
| Operating Cash Flow | $2,489,823 | $1,662,675 | $960,060 | $596,076 | $2,768,986 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -1,697,729 | N/A | N/A | N/A | -2,505,701 |
| PPE Investments | N/A | -964,044 | -2,171 | -1,057 | -18,000 |
| Net Acquisitions | -74,416 | -74,416 | -74,190 | N/A | N/A |
| Purchase Of Investment | -504,740 | -348,027 | -348,027 | -54,427 | -298,455 |
| Sale Of Investment | 671,651 | 629,054 | 625,269 | 559,401 | 142,002 |
| Other Investing Activity | -8,946 | -8,946 | -8,946 | 0 | 2,039 |
| Investing Cash Flow | $-1,614,180 | $-766,379 | $191,935 | $503,917 | $-2,678,115 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,275,000 | 1,275,000 | N/A | N/A | N/A |
| Debt Issued | 1,954,475 | 1,954,475 | N/A | N/A | 1,471,235 |
| Debt Repayment | -1,000,000 | -1,000,000 | N/A | N/A | N/A |
| Common Stock Issued | 5,917 | 5,917 | 6,121 | 1,297 | 5,107 |
| Common Stock Repurchased | -1,227,383 | -1,146,846 | -1,000,353 | -708,781 | -229,651 |
| Dividend Paid | -900,629 | -686,381 | -454,881 | -233,815 | -863,904 |
| Other Financing Activity | -1,293,353 | -1,288,543 | 0 | 0 | -21,642 |
| Financing Cash Flow | $-1,185,973 | $-886,378 | $-1,449,113 | $-941,299 | $361,145 |
| Beginning Cash Position | 929,026 | 929,026 | 929,026 | 929,026 | 477,010 |
| End Cash Position | 618,696 | 938,944 | 631,908 | 1,087,720 | 929,026 |
| Net Cash Flow | $-310,330 | $9,918 | $-297,118 | $158,694 | $452,016 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,489,823 | 1,662,675 | 960,060 | 596,076 | 2,768,986 |
| Capital Expenditure | N/A | -964,044 | -2,171 | -1,057 | -18,000 |
| Free Cash Flow | 2,489,823 | 698,631 | 957,889 | 595,019 | 2,750,986 |